TITLE

Clinical Features and Prognostic Factors Associated with Adrenocortical Carcinoma: Lahey Clinic

AUTHOR(S)
Tritos, Nicholas A.; Cushing, Gary W.
PUB. DATE
January 2000
SOURCE
American Surgeon;Jan2000, Vol. 66 Issue 1, p73
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Adrenocortical carcinoma is a rare tumor associated with a commonly poor prognosis. However, data on the natural history and response to therapy of patients with this malignancy have often been conflicting. Our objective of this retrospective study was to evaluate the clinical course and survival of patients with adrenocortical carcinoma and to identify relevant prognostic factors. Between 1966 and 1996, 31 patients with histologically documented adrenocortical carcinoma were observed at the Lahey Clinic Medical Center. Patient information was obtained from chart review. At the time of diagnosis, 48 per cent of patients had endocrine symptoms with compatible hormonal studies, 19 per cent had involvement of the inferior vena cava by tumor thrombus, and 32 per cent had metastatic disease. The median survival time was 17 months (range, 1-205 months) for the entire group, and the 5-year survival rate was 26 per cent. Age <54 years, absence of metastatic disease at the time of diagnosis, and completeness of surgical resection were associated with better prognosis. Evaluation of survival with the Cox proportional hazards model suggested that age <54 years, absence of metastatic disease, and nonfunctioning tumor status were independently associated with improved survival. The prognosis of patients with adrenocortical carcinoma is poor but appears more favorable in patients <54 years, with localized disease, or nonfunctioning tumor status. Complete tumor resection may be associated with improved survival.
ACCESSION #
2723514

 

Related Articles

  • o,p'DDD therapy in invasive adrenocortical carcinoma. Becker, Dennis; Schumacher, O. Peter; Becker, D; Schumacher, O P // Annals of Internal Medicine;May75, Vol. 82 Issue 5, p677 

    Invasive adrenocortical carcinoma was diagnosed in two patients, 3 1/2 and 69 years of age, respectively. Therapy with o,p'DDD was begun immediately, and the patients have survived 4 1/12 and 7 9/12 years, respectively. The prolonged survival represents possible "cure" of inoperable disease...

  • Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. Nishimura, Kazuo; Nonomura, Norio; Satoh, Eiichi; Harada, Yasunori; Nakayama, Masashi; Tokizane, Takashi; Fukui, Tatsunari; Ono, Yutaka; Inoue, Hitoshi; Shin, Masaru; Tsujimoto, Yuichi; Takayama, Hitoshi; Aozasa, Katsuyuki; Okuyama, Akihiko; Nishimura, K; Nonomura, N; Satoh, E; Harada, Y; Nakayama, M; Tokizane, T // JNCI: Journal of the National Cancer Institute;11/21/2001, Vol. 93 Issue 22, p1739 

    Background: Dexamethasone, a synthetic glucocorticoid, has clinical benefit in patients with hormone-refractory prostate cancer (HRPC), but the mechanisms responsible for its effects are unknown. The nuclear factor-kappaB (NF-kappaB)-dependent cytokine interleukin (IL) 6 (IL-6) is...

  • Eating to prevent cancer.  // Joe Weider's Muscle & Fitness;Feb95, Vol. 56 Issue 2, p37 

    Reports on the possibility that food fasting may help in the prevention of cancer. Findings on animal experiments; Effect of stress hormone corticosteroid; Effect of restricted energy intake.

  • Corticosteroids in advanced cancer. Twycross, Robert // BMJ: British Medical Journal (International Edition);10/24/92, Vol. 305 Issue 6860, p969 

    Investigates the effectiveness of corticosteroids for treatment of patients with advanced cancer in Great Britain. Effect of corticosteroids treatment on the aged patients with cancer; Benefits of patients with breast and prostate cancer in using the hormone; Characteristics of the corticosteroids.

  • When the patient says "no.". Kloub, A. G. // Eastern Mediterranean Health Journal;nov/dic2009, Vol. 15 Issue 6, p1621 

    The article describes the case of a 55-year-old woman with cancer who was able to continue to exercise her free will and to participate actively in her medical management until her death through an empowering and transparent patient-doctor relationship. The patient had proximal bowel obstruction...

  • Immune Checkpoint Blockade in Cancer Treatment: A Double-Edged Sword Cross-Targeting the Host as an "Innocent Bystander". Gelao, Lucia; Criscitiello, Carmen; Esposito, Angela; Goldhirsch, Aron; Curigliano, Giuseppe // Toxins;Mar2014, Vol. 6 Issue 3, p914 

    Targeted immune checkpoint blockade augments anti-tumor immunity and induces durable responses in patients with melanoma and other solid tumors. It also induces specific "immune-related adverse events" (irAEs). IrAEs mainly include gastrointestinal, dermatological, hepatic and endocrinological...

  • Usefulness of corticosteroid therapy during chronic disseminated candidiasis: case reports and literature review. Chaussade, H.; Bastides, F.; Lissandre, S.; Blouin, P.; Bailly, E.; Chandenier, J.; Gyan, E.; Bernard, L. // Journal of Antimicrobial Chemotherapy (JAC);Jun2012, Vol. 67 Issue 6, p1493 

    Objectives Chronic disseminated candidiasis (CDC) is a disseminated fungal infection that is frequently seen in patients undergoing intensive treatment of haematological malignancies. The first signs of CDC appear during neutrophil recovery. Clinical and physiopathological characteristics of CDC...

  • INFLAMMATION AND CANCER: CYCLO OXYGENASE PRODUCTS OVERRIDE THE ANTI-TUMOUR EFFECTS OF ELEVATED CORTICOSTEROIDS INDUCED BY CONTROLLED FEEDING IN MICE.  // Immunology & Cell Biology;Dec1993, Vol. 71 Issue 6, special section pS9 

    The article presents studies that show that inflammation can potentiate the development of tumours at a distant site and that reduced corticosteroid secretion assists such tumour growth. Controlled-feeding (CF), 18 hours fasting/6 hours feeding, significantly inhibited the growth of spontaneous...

  • Aprepitant: a substance P antagonist for chemotherapy induced nausea and vomiting. Girish, C.; Manikandan, S. // Indian Journal of Cancer;Jan-Mar2007, Vol. 44 Issue 1, p25 

    The episodes of nausea and vomiting which follow each cycle of chemotherapy are the most troublesome side effect experienced by cancer patients. Introduction of ondansetron was a definite therapeutic advance in treating chemotherapy induced nausea and vomiting (CINV) with more effectiveness with...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics